Related Experiment Video

Updated: Jul 5, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

[Lipid and carbohydrate disturbances in men with coronary artery disease according to age]

Elwira Stasiakowska-Badura1, Marek Kochmański

  • 1Klinika Kardiologii Zachowawczej Centralnego Szpitala Klinicznego MSWiA w Warszawie.

Polskie Archiwum Medycyny Wewnetrznej
|April 18, 2008
PubMed

Insights

Higher HDL cholesterol and ApoAI levels are linked to lower coronary artery disease (CAD) risk in men. These lipid markers, particularly high-density lipoprotein (HDL) cholesterol, may indicate reduced atherosclerosis.

Area of Science:

  • Cardiology
  • Clinical Biochemistry
  • Preventive Medicine

Background:

  • Coronary artery disease (CAD) is a significant health concern, influenced by various risk factors.
  • Lipid and carbohydrate metabolism plays a crucial role in the development of atherosclerosis.
  • Understanding age-related differences in CAD risk factors is essential for targeted prevention.

Purpose of the Study:

  • To identify factors associated with coronary artery disease (CAD) in men.
  • To compare lipid and carbohydrate parameters between younger and older men with and without CAD.
  • To investigate the relationship between specific lipid profiles and the presence of coronary atherosclerosis.

Main Methods:

  • Study included 60 men with stable CAD and 33 controls, divided into younger (<60) and older (>70) age groups.
  • Serum lipid profiles, including apolipoprotein AI (ApoAI) and B, were analyzed.
  • Oral glucose tolerance tests were performed; fasting glucose was assessed.

Main Results:

  • Control groups (without CAD) showed significantly higher high-density lipoprotein (HDL) cholesterol and ApoAI levels compared to CAD groups.
  • A weak positive correlation was observed between fasting glucose concentration and CAD presence.
  • Younger and older men with CAD differed significantly in HDL cholesterol levels, with a strong correlation to HDL ApoAI.

Conclusions:

  • Higher concentrations of HDL cholesterol and ApoAI are associated with a reduced risk of coronary artery disease in men.
  • Fasting glucose may have a minor role, while HDL cholesterol and ApoAI appear to be more significant indicators of CAD.
  • Family history of heart disease was more prevalent in younger patients with CAD.

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...